MPM Oncology Impact Management »

Allakos shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Allakos (ALLK) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Allakos

Tip: Access up to 7 years of quarterly data

All positions including Allakos held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Allakos by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $345k 345k 1.00

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Allakos

BVF
NEA Management Company
Deep Track Capital
Vanguard Group
Redmile Group
Logos Global Management
Opaleye Management
Acadian Asset Management
Citadel Advisors
Morgan Stanley
Point72 Asset Management
BlackRock
BlackRock
Rock Springs Capital Management
Platinum Investment Mangement

View all funds holding Allakos